Investigational Drug Information for Tirapazamine
✉ Email this page to a colleague
What is the development status for investigational drug Tirapazamine?
Tirapazamine is an investigational drug.
There have been 21 clinical trials for Tirapazamine.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2000.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Head and Neck Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Teclison Ltd., and Southwest Oncology Group.
Summary for Tirapazamine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,612 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,130 |
| Clinical Trial Progress | Phase 3 (2000-11-01) |
| Vendors | 53 |
Recent Clinical Trials for Tirapazamine
| Title | Sponsor | Phase |
|---|---|---|
| TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Merck Sharp & Dohme Corp. | Phase 2 |
| TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Teclison Ltd. | Phase 2 |
| TATE Versus TACE in Intermediate Stage HCC | Teclison Ltd. | Phase 2 |
Clinical Trial Summary for Tirapazamine
Top disease conditions for Tirapazamine
Top clinical trial sponsors for Tirapazamine
US Patents for Tirapazamine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
